⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
COYA News
Coya Therapeutics, Inc. Common Stock
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
businesswire.com
COYA
Form 8-K
sec.gov
COYA
Form 8-K
sec.gov
COYA
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
businesswire.com
COYA
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
businesswire.com
COYA
Exosome Therapy Market Size and Industry Dynamics 2026-2035 - Standardization Challenges Loom Over Booming $58 Billion Exosome Therapy Industry
globenewswire.com
CRBP
CAPR
AEMD
COYA
EVOX
Form 8-K
sec.gov
COYA
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
businesswire.com
COYA
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
businesswire.com
COYA
Form 8-K
sec.gov
COYA